Please read the entire editorial here. I pared the article down as much as I could here so you get the gist.Women pay approximately 48% more for health care than do men in the United States. Even after paying high health care premiums to health insurance companies, women are sometimes denied coverage of pregnancy and childbirth care because it is deemed a pre-existing condition.
In the latest form of the health care reform bill, Bart Stupak, (D), MI., proposed an amendment that would exclude abortion care and treatment from health insurance for women, not just government funded health care such as Medicare or a public option but by any private health care insurance company as well. The Stupak amendment passed and if it isn't cut from the bill, women will find themselves with few choices.
Coming just days after the Stupak amendment was voted on and passed, a private sector task force commissioned by the Health and Human Services division of the U.S. government announced that it would recommend that physicians forego advising female patients under the age of 50 to have annual screening for breast cancer. The U.S. Preventative Service Task Force (USPSTF) panel of 16 included three private health insurance company representatives but no oncologists. The panel measured some number models and came up with the recommendation, ostensibly because of a higher number of 'false positives' among women under 50, causing anxiety and sometimes, unnecessary followups and testing.
It's widely known that the United States ranks far below other developed nations in health care costs, treatment results, and lifespan but one of the few areas in which the U.S. has excelled has been in preventing cancer deaths. It is unclear why the USPSTF has recommended suspension of annual mammograms for women under 50.
According to the Washington Post, "Many experts have begun to raise questions about routine screening methods, including the PSA blood test for prostate cancer and mammography, because they often trigger false alarms and catch precancerous growths and tiny tumors that would never become life-threatening but nonetheless prompt treatment."
But so far, the USPSTF hasn't recommended suspending testing for prostate cancer in men under the age of 75.
In August of 2008, the USPSTF made recommendations regarding prostate cancer screening that is very different than its recommendations for breast cancer screening.
So in 2008, the USPSTF in essence, recommends that physicians discuss the benefits and risks of prostate cancer screening with their male patients under the age of 75 and decide what action to take, if any.
Both prostate cancer and breast cancer screening effectiveness has been controversial in the last decade but the USPSTF appears to believe that physicians and their male patients can discuss the controversy and come to a decision about whether or not to be tested and how to be treated. Yet their recommendations that physicians forego recommending any sort of breast cancer screening to their female patients seem to indicate that the 15% of women between 40-49 whose deaths are prevented by screening aren't worth the bother of having to explain what the options, benefits and risks of breast cancer screening are to women.